Compare e l f Beauty Inc (ELF) vs Cassava Sciences Inc (FLNA) Price & Performance

ELF Beauty trades at $76.11, up 5.34% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins remain thin at 1.61%. Recent analyst coverage is mixed with 46% buy ratings and consensus target of $74.42, slightly below current price. The company demonstrates solid operational cash flow of $133.84M and maintains a healthy balance sheet with $148.69M cash.

Outlook remains positive with continued double-digit sales growth targets, though elevated P/E ratio of 168.68 presents valuation concerns. Key risks include tariff exposure and core brand momentum challenges. Institutional sentiment leans bullish with recent price momentum supported by earnings outperformance and strategic expansion into skincare categories.

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.